Juno Therapeutics, Inc. (JUNO) Receives Buy Rating from Maxim Group

Maxim Group restated their buy rating on shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) in a report released on Thursday, November 2nd. They currently have a $56.00 price objective on the biopharmaceutical company’s stock.

Several other analysts also recently commented on JUNO. Vetr upgraded shares of Juno Therapeutics from a strong sell rating to a sell rating and set a $25.50 price target for the company in a research report on Monday, August 14th. Zacks Investment Research downgraded shares of Juno Therapeutics from a hold rating to a sell rating in a research report on Thursday, August 10th. Morgan Stanley upped their price target on shares of Juno Therapeutics from $26.00 to $27.00 and gave the company an equal weight rating in a research report on Monday, August 7th. Leerink Swann reiterated an in-line rating and issued a $56.00 price target (up previously from $34.00) on shares of Juno Therapeutics in a research report on Thursday, November 2nd. Finally, Raymond James Financial, Inc. upgraded shares of Juno Therapeutics from a market perform rating to an outperform rating and set a $45.00 price target for the company in a research report on Tuesday, August 29th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of $44.20.

Shares of Juno Therapeutics (JUNO) opened at $58.77 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.77 and a current ratio of 4.77. Juno Therapeutics has a 12-month low of $17.52 and a 12-month high of $61.59.

Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The business had revenue of $44.80 million during the quarter, compared to the consensus estimate of $18.12 million. During the same quarter in the previous year, the firm earned ($0.57) EPS. The company’s revenue was up 115.4% compared to the same quarter last year. sell-side analysts forecast that Juno Therapeutics will post -4.02 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Juno Therapeutics, Inc. (JUNO) Receives Buy Rating from Maxim Group” was posted by BBNS and is the sole property of of BBNS. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://baseballnewssource.com/markets/juno-therapeutics-inc-juno-given-buy-rating-at-maxim-group/1753311.html.

In related news, EVP Robert Azelby sold 6,666 shares of the stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $54.95, for a total value of $366,296.70. Following the sale, the executive vice president now directly owns 79,998 shares of the company’s stock, valued at approximately $4,395,890.10. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, General Counsel Bernard J. Cassidy sold 28,000 shares of the stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $44.92, for a total transaction of $1,257,760.00. Following the completion of the sale, the general counsel now directly owns 55,970 shares in the company, valued at $2,514,172.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 79,670 shares of company stock worth $3,553,777. Corporate insiders own 15.26% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Utah Retirement Systems grew its stake in Juno Therapeutics by 1.8% in the 2nd quarter. Utah Retirement Systems now owns 11,600 shares of the biopharmaceutical company’s stock valued at $347,000 after acquiring an additional 200 shares during the last quarter. State of Wisconsin Investment Board lifted its holdings in Juno Therapeutics by 1.7% in the 2nd quarter. State of Wisconsin Investment Board now owns 12,562 shares of the biopharmaceutical company’s stock valued at $375,000 after purchasing an additional 210 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Juno Therapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 228 shares in the last quarter. Aperio Group LLC lifted its holdings in Juno Therapeutics by 4.2% in the 3rd quarter. Aperio Group LLC now owns 29,554 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 1,194 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in Juno Therapeutics by 9.5% in the 3rd quarter. SG Americas Securities LLC now owns 15,254 shares of the biopharmaceutical company’s stock valued at $684,000 after purchasing an additional 1,328 shares in the last quarter. 66.96% of the stock is currently owned by hedge funds and other institutional investors.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.